Skip to main content

Unicycive: The Company Developing Key Kidney Therapies

--News Direct--

Doug Jermasek, Executive Vice President, Corporate Strategy for Unicycive Therapeutics, Inc. (NASDAQ: UNCY), was recently interviewed by Benzinga.

Unicycive is a biotechnology company focused on solutions for important and underserved renal diseases. The company currently has two key technologies in the development pipeline.

UNI-494 works primarily to help the mitochondria in cells perform better, which in turn may help with Acute Kidney Injury (AKI). The company’s other technology, Renazorb, is currently being developed as an Investigative New Drug (IND). If approved, the drug will help patients significantly reduce their daily pill burden in the treatment of hyperphosphatemia.

Watch the full interview here:

Featured photo by Hal Gatewood on Unsplash

Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug, Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia. UNI-494 is a patent-protected new chemical entity in late preclinical development for the treatment of acute kidney injury.

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.

Contact Details

Anne Marie Fields - Stern Investor Relations

+1 212-362-1200

Company Website

View source version on

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.